Table 1 Model parameters and estimations
From: Antiviral resistance during pandemic influenza: implications for stockpiling and drug use
| parameter | description | baseline value | references |
|---|---|---|---|
| 1/μ A | mean infectious period of asymptomatic infection | 4.1 days | [3, 6, 7] |
| 1/μ U | mean infectious period of untreated symptomatic infection | 4.1 days | [3, 6, 7] |
| 1/μ T | mean infectious period of treated symptomatic infection | 4.1 days | [3, 6, 7] |
| d U | death rate of untreated symptomatic infection | 0.002 day-1 | [12, 19] |
| d T | death rate of treated symptomatic infection | 0.001 day-1 | [12, 19] |
| d U,r | death rate of resistant infection (low fitness) | 0.0002 day-1 | [12, 19] |
| d r,U | death rate of resistant infection (high fitness) | 0.0008 day-1 | [12, 19] |
| δ A | relative transmissibility of asymptomatic infection | 0.142 | [6, 7, 19] |
| δ T | relative transmissibility of treated symptomatic infection | 0.4 | [3, 12, 19] |
| δ r | relative transmissibility of resistant strain (high fitness) | 0.9 | [19, 27] |
| p | probability of developing clinical symptoms | 0.67 | [6, 7] |
| α | rate of emergence of de novo resistance | 0.018 day-1 | [19, 25] |
| γ | rate of conversion between resistant mutants | 0.0036 day-1 | [19, 25] |
| q | treatment level | variable |